Big Boogie confirms sister Laterrika Woods died in Arkansas police chase
Memphis rapper Big Boogie, born John Lotts, is mourning the tragic loss of his sister, Laterrika Woods, who reportedly died during a high-speed police chase in Arkansas on or around March 26, 2025. The crash also left another woman, Taricaa Lashay, seriously injured—she reportedly lost an arm. While official details are still pending, widespread social media reports, including a confirmation video from Big Boogie himself, have drawn national attention.
According to circulating posts on X, the incident began when a vehicle driven by an individual identified as Kizzle Consistent FlyGuy was involved in a police pursuit. Reports allege Arkansas police rammed the SUV, causing it to flip. Woods, who was a passenger, died at the scene. Lashay, another occupant, suffered life-altering injuries. As of now, the Arkansas State Police have not released a formal statement about the chase.
Memphis rapper Big Boogie's sister Laterrika Woods reportedly passed away in a car accident in Arkansas, and another victim Taricaa Lashay lost an arm. Reports allege police rammed a vehicle driven by Kizzle Consistent FlyGuy during a chase. pic.twitter.com/szDXM7fl2A — Kollege Kidd (@KollegeKidd) March 26, 2025
The controversy intensified after users on X, including @KollegeKidd, alleged that police deliberately used a tactical maneuver—potentially the PIT (Precision Immobilization Technique)—to stop the vehicle. Critics argue these aggressive tactics carry high risks, especially for passengers uninvolved in criminal activity. Woods' death has reignited debate around Arkansas' pursuit policies.
Earlier this month, the Arkansas Advocate reported that police conducted 553 car chases in 2024, resulting in six fatalities. State officials had pledged a tougher stance on suspects fleeing law enforcement, but the latest incident is prompting renewed scrutiny.
Woods, remembered as a mother, has been mourned widely online, with many questioning the necessity and proportionality of the chase. The hip-hop community has rallied around Big Boogie, who is signed to Yo Gotti's Collective Music Group. Fans and followers have flooded social media with tributes, demanding accountability and transparency.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board
PALO ALTO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, 'Scilex' or 'Company'), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors (the 'Board') has approved a deferral of the previously announced record date of May 2, 2025 for the Company's previously announced dividend of Scilex preferred stock (the 'Dividend') to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be such later date to be determined in the sole discretion of the Board (such later record date as so determined by the Board, the 'New Record Date'). The Board retains the right to continue to change any New Record Date (and therefore any related payment date for the Dividend) and the ability to revoke the Dividend. For more information on Scilex Holding Company, refer to For more information on Semnur Pharmaceuticals, Inc., refer to For more information on ZTlido® including Full Prescribing Information, refer to For more information on ELYXYB®, including Full Prescribing Information, refer to For more information on Gloperba®, including Full Prescribing Information, refer to info@ About Scilex Holding Company Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex's commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the 'FDA') for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) ('SEMDEXA' or 'SP-102'), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, ('SP-103'), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) ('SP-104'), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia. Scilex Holding Company is headquartered in Palo Alto, California. About Semnur Pharmaceuticals, Inc. Semnur Pharmaceuticals, Inc. ('Semnur') is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur's product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica. Semnur Pharmaceuticals, Inc. is headquartered in Palo Alto, California. Forward-Looking Statements This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Scilex's declaration and payment of the Dividend and timing thereof (including that the Board may change the New Record Date and, as a result, the payment date for the Dividend), Scilex's potential development and commercialization of treatments for obesity, neurodegenerative, cardiometabolic disease. Risks and uncertainties that could cause Scilex's actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks associated with the Board's right to change the New Record Date and/or revoke the Dividend, Scilex's ability to develop and commercialize treatments for obesity, neurodegenerative, cardiometabolic disease; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex's common stock; general economic, political and business conditions; risks related to COVID-19 (and other similar disruptions); the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex's product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex's product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex's most recent periodic reports filed with the Securities and Exchange Commission, including Scilex's Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file with the SEC, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law. Contacts: Investors and MediaScilex Holding Company 960 San Antonio RoadPalo Alto, CA 94303Office: (650) 516-4310 Email: investorrelations@ Website: SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned. ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company. ELYXYB® is a registered trademark owned by Scilex Holding Company. Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc. All other trademarks are the property of their respective owners. © 2025 Scilex Holding Company All Rights in to access your portfolio
Indian Express
4 minutes ago
- Indian Express
Early-season heat dome brings highest temperatures in years to parts of Eastern US
An intense and nearly historic weather pattern is cooking much of America under a dangerous heat dome this week with triple-digit temperatures in places that haven't been so hot in more than a decade. The heat wave is especially threatening because it's hitting cities like Boston, New York and Philadelphia early in the summer when people haven't gotten their bodies adapted to the broiling conditions, several meteorologists said. The dome of high pressure that's parking over the eastern United States is trapping hot air from the Southwest that already made an uncomfortable stop in the Midwest. A key measurement of the strength of the high pressure broke a record Monday and was the third-highest reading for any date, making for a 'near historic' heat wave, said private meteorologist Ryan Maue, a former National Oceanic and Atmospheric Administration chief scientist. The worst of the heat was likely to peak for Northeastern cities on Tuesday, forecasters said. 'Like an air fryer, it's going to be hot,' Maue said. 'This is a three-day stretch of dangerous heat that will test the mettle of city dwellers who are most vulnerable to oppressive heat waves.' A heat dome occurs when a large area of high pressure in the upper atmosphere acts as a reservoir, trapping heat and humidity.A heat wave is the persistence of heat, usually three days or more, with unusually hot temperatures. Nearly three-quarters of the country's population — 245 million people — will swelter with 90 degrees Fahrenheit (about 32 Celsius) or higher temperatures on Monday, and 33 million people, almost 10% of the country, will feel blistering 100-degree heat (about 38 Celsius) on Tuesday, Maue said. The government's heat health website showed the highest level of heat risk in swaths from Chicago to Pittsburgh and North Carolina to New York. Those triple-digit air temperatures — with the feels-like index even worse because of humidity — are possible in places where it's unusual. New York hasn't seen 100 degrees since 2011 and Philadelphia, which is forecast to have consecutive triple-digit days, hasn't reached that mark since 2012, said Climate Central chief meteorologist Bernadette Woods Placky. In downtown Baltimore, temperatures climbed into the high 90s by early Monday afternoon, bringing dozens of people to cool off at St. Vincent de Paul's resource center. A few blocks away, the city's historic Broadway Market food hall closed early when the building's air conditioning broke. The heat forced the cancellation of events in west Baltimore, said Eric Davis Sr., who spends most of his days working at a baseball field there. 'You can't have kids getting heat stroke,' he said. 'It's just too hot today.'NOAA meteorologist David Roth said it takes time to acclimate to summer heat and this heat dome could be a shock for some. 'You're talking about some places that could be 40 degrees warmer than last week. So that's a big deal,' he said. The heat is part of Earth's long-term warming. Summers in the United States are 2.4 degrees (1.3 degrees Celsius) hotter than 50 years ago, according to NOAA data. Human-caused climate change has made this heat wave three times more likely than without the burning of coal, oil and gas, the climate science nonprofit Climate Central calculated, using computer simulations comparing the current weather to a fictional world without the industrial greenhouse gases. A key question is how much humidity will add to the discomfort and danger of the heat. Maue is forecasting dry air which may be a degree or two or three hotter than predicted by NOAA, but more comfortable. Other meteorologists expected worse: Sticky, humid and even more dangerous.' The 'big deal' will be with the humidity being provided with the wet late spring conditions,' said University of Oklahoma meteorology professor Jason Furtado. 'The area of high pressure will allow for a lot of evaporation to occur from the wet grounds locally and regionally, which will increase the heat indices quite a bit.' Woods Placky said to expect dew points, a key measure of humidity, in the 70s. That's downright tropical, with some places approaching a dew point of 80 — a level Woods Placky said feels like 'you're in a swimming pool' and 'the atmosphere is absorbing you.' If this heat were later in the summer, it might not be as dangerous because the human body can adjust to the seasonably warmer temperatures, but this one is coming within days of the solstice, Woods Placky and others said. 'It will be a shock to the system,' she said.
Indian Express
4 minutes ago
- Indian Express
Name announced before EC's date, top leadership campaigning in Gujarat: How bet on Italia paid off for AAP in bypoll
On March 23, even before the Election Commission could announce the date for bypolls, the Aam Aadmi Party (AAP) declared the candidature of former party chief in the state, Gopal Italia, for the Visavadar seat. In the run-up to the election, held on June 19, the top leadership of the party – from National Convener Arvind Kejriwal to Punjab Chief Minister Bhagwant Mann – arrived in the constituency in Junagadh district of Gujarat, putting their weight firmly behind Italia. The bet clearly paid off for the party with Italia retaining the seat for the AAP after defeating Bharatiya Janata Party's (BJP) Kirit Patel by 17,554 votes. In Kadi, the other seat that went to bypolls, BJP's Rajendra Chavda emerged as the winner. Addressing media persons after the results were declared, Italia termed the 'historic' victory as that of the people of Visavadar. 'This election is a milestone one. The BJP had deployed all its might in it. But a new example has emerged before the people of Gujarat (highlighting) that the might of power, money, muscle power, administration is not what is bigger… It is the might of people's resolve that is the biggest power in the country. The brave people of Visavadar have proved it.' Italia called upon the youths to come forward 'to uproot the BJP from Gujarat' and to bring about change in the state. This was Italia's second electoral contest for a seat of Gujarat Assembly. In December 2022, he fought the election from Katargam constituency of Surat. However, he lost to the BJP's Vinu Moradia. With these results, the BJP's tally in the 182-member Gujarat Assembly has risen to 162 whereas the number of AAP members has, once again, gone up to five. Congress has 12 members followed by one legislator of the Samajwadi Party. Two members are independents. The bypolls to the two seats were necessitated as AAP's sitting MLA from Visavadar, Bhupendra Bhayani, had resigned in 2023 and later joined the BJP. The Kadi seat, on the other hand, had fallen vacant after the demise of the sitting MLA, BJP's Karsan Solanki. Among the by-elections of the two seats, the contest on Visavadar constituency was keenly watched. The AAP was seen to be fighting the election here quite aggressively, nominating Italia on the seat even before the elections were announced. AAP's top leadership including Kejriwal, senior leader Atishi, and Punjab CM Mann had landed in Gujarat and accompanied Italia as he filed his nomination papers. Congress had fielded Nitin Ranpariya on the seat who registered only 5,501 votes despite top party leaders such as Shaktisinh Gohil, Jignesh Mevani and Paresh Dhanani campaigning for him. The BJP, too, had aggressively campaigned for the Visavadar seat in an attempt to break its jinx with the constituency, which was once represented by former Chief Minister Keshubhai Patel. It was way back in 2007, when the BJP's Kanubhai Bhalala had won the Assembly election from the constituency. The Kadi constituency also saw a three-pronged contest. Apart from the BJP's Rajendra Chavda and the Congress's Ramesh Chavda, AAP's Jagdish Chavda were in the fray. While Rajendra won by a big margin of 39,452 votes, Jagdish recorded 3,090 votes. In 2022, AAP's Bhupendra Bhayani had defeated BJP's Harshad Ribadiya, a Congress turncoat, in the Visavadar seat by 7,063 votes. Bhayani had registered a total of 59,147 seats. In the recent by-election, Italia registered much higher number of votes (75,942). In 2022, the Kadi constituency was won by BJP's Solanki by a margin of 28,194 votes. In the by-election, BJP has retained the seat by a higher margin of 39,452 votes.
